CANY
HAE icon

Caxton Associates (New York)’s Haemonetics HAE Stock Holding History

Caxton Associates (New York)’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,528
Closed -$346K – 589
2021
Q4 		$346K Buy
+6,528
New +$398K 0.04% 372
2020
Q2 		– Sell
-2,047
Closed -$204K – 532
2020
Q1 		$204K Buy
+2,047
New +$222K 0.04% 347
2019
Q3 		– Sell
-2,467
Closed -$297K – 453
2019
Q2 		$297K Buy
+2,467
New +$243K 0.04% 286
2018
Q4 		– Sell
-2,710
Closed -$311K – 364
2018
Q3 		$311K Buy
+2,710
New +$281K 0.02% 317

Other funds holding HAE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LCOV
London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Caxton Associates (New York)'s HAE Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Haemonetics (HAE) in Q1 2022, closing a stake of 6,528 shares — an estimated $346K sold.

Caxton Associates (New York) first reported a position in HAE in Q3 2018 and held it in 4 quarters. The position peaked at $346K in Q4 2021. 242 funds tracked by Wall St. Rank hold HAE as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Haemonetics position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 6,528 Haemonetics shares in Q1 2022, an estimated $346K.
  • Caxton Associates (New York) first reported a position in Haemonetics in Q3 2018 and held it in 4 quarters.
  • Caxton Associates (New York)'s Haemonetics position peaked at $346K in Q4 2021.
  • 242 funds tracked by Wall St. Rank held Haemonetics as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.